Singapore markets closed

Vaxart, Inc. (VXRT)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.5806+0.0082 (+1.43%)
As of 09:44AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close0.5724
Bid0.5634 x 200
Ask0.6029 x 200
Day's range0.5800 - 0.6300
52-week range0.5300 - 1.5400
Avg. volume2,653,904
Market cap102.672M
Beta (5Y monthly)0.65
PE ratio (TTM)N/A
EPS (TTM)-0.5200
Earnings date01 Aug 2024 - 05 Aug 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date09 Nov 2012
1y target est5.25
  • Benzinga

    Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering

    Vaxart, Inc. (NASDAQ:VXRT) shares traded higher in the premarket session on Friday, up more than 23% at one point. Vaxart’s average session volume was about 1.6 million. Friday premarket’s session volume had exceeded four million at the time of writing. Yesterday, Vaxart obtained a project award worth $453 million through the Rapid Response Partnership Vehicle, supported by the Biomedical Advanced Research and Development Authority under the Administration for Strategic Preparedness and Response

  • GlobeNewswire

    Vaxart Announces $40 Million Underwritten Offering of Common Stock

    SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per share, which is a premium to the last closing price of $0.75 per share. Gross proceeds to Vaxart from the offering are expected to be $40 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Vaxart. The offering is expected to

  • GlobeNewswire

    Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

    — 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early as summer 2024 — SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) announced today that it received a project award valued at up to $453 million through the Rapid Response Partnership Vehicle (RRPV). The RRPV is a Consortium funded by the Biomedical Advanced Rese